Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for preventing ischemia reperfusion injury in organs

a technology of ischemia and reperfusion injury, applied in drug compositions, extracellular fluid disorders, cardiovascular disorders, etc., can solve the problem of imposing the risk of iri in the native organ by inhibiting or using the risk of iri, and achieve the effect of reducing the amount and duration of dialysis and improving clinical outcomes

Inactive Publication Date: 2017-03-23
QUARK FARMACUITIKALS INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a new discovery that shows that people who receive kidneys from dead donors over the age of 35 have better outcomes when treated with a temporary p53 inhibitor. This treatment also reduces the need for dialysis after transplantation. The text suggests that using temporary p53 inhibitors may be a beneficial treatment for kidneys from older donors, regardless of their quality.

Problems solved by technology

In some embodiments of the method, inhibitor or use the risk of IRI in the native organ is imposed by temporary cessation of blood flow to the organ or by temporary global hypoxia of the organ.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for preventing ischemia reperfusion injury in organs
  • Methods and compositions for preventing ischemia reperfusion injury in organs
  • Methods and compositions for preventing ischemia reperfusion injury in organs

Examples

Experimental program
Comparison scheme
Effect test

example 1

Ischemia-Reperfusion Induced p53 Activation in Kidneys from Rat Donors

[0160]Kidneys were harvested from young (3-month old) and old (14-month old) SD rats (n=4-6) and subjected to cold ischemia (CI) for 5 hours. One kidney from each animal was processed for protein extraction whereas the second kidney was transplanted into 3-month old syngeneic rats. The transplanted kidneys were harvested 24 hours after the surgery and the resultant onset of ischemia-reperfusion injury (IR) and also processed for protein extraction. Protein extracts were analyzed in ELISA for p53 expression levels.

[0161]Results: In FIG. 1, the Y-axis shows arbitrary units corresponding to p53 protein levels measured in ELISA. FIG. 1 shows that the p53 protein level is significantly increased in transplanted kidneys from older rats, compared to transplanted kidneys from young rats (3 months old). Note that following p53 activation occurring via a variety of post-translational modifications, its steady-state levels a...

example 2

Use of an Inhibitor of a p53 Gene for Prophylaxis of Delayed Graft Function (DGF) in a Recipient of a Kidney from Donors of Various Ages.

[0251]A study similar to Example 1 was performed to test the effectiveness of QPI-1002 using kidneys from donors of various ages that did not necessarily meet the criteria for ECD donors.

[0252]In the efficacy analysis, the best primary endpoint results were obtained for patients receiving kidneys from donors older than 45 years of age (regardless of their primary subgroup classification) that constituted 77% of all the evaluable patients in the study). Importantly, a threshold of 35 years of age (86% of all the evaluable patients in the study regardless of subgroup classification) yielded similar benefits (listed below):

[0253]Clinically meaningful and, in some subgroups, statistically significant reduction in the incidence of dialysis in the first week post-transplant—the primary endpoint of this study.

[0254]Clinically meaningful reductions in the ...

example 3

Dialysis Analysis in Phase II Study

[0257]Objective: Dialysis has a pharmacoeconomic impact as well as health consequences. Therefore, a comparison of the number of dialyses from day 0 to day 180 between treatment groups is of interest.

[0258]Statistical Methods: to compare between treatment groups (I5NP, Placebo)[0259]Zero-inflated Poisson regression model (ZIP), which is a statistical model based on a Poisson probability distribution that allows for frequent zero-valued observations. The dialysis count per patient variable is of such nature.[0260]Sensitivity analysis: Non-parametric test: Wilcoxon and Median[0261]Descriptive statistics: using counts, mean, standard deviation (SD), median, minimum and maximum

[0262]The analysis was not limited to the first course only or conditioned on DGF event.

[0263]Analysis scheme: The analysis was performed on the mitt(EE) population.[0264]Over all patients[0265]Donor age>35 years patient group[0266]Donor age>45 years patient group

[0267]Study Dura...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.

Description

SEQUENCE LISTING[0001]This application incorporates-by-reference nucleotide and / or amino acid sequences which are present in the file named “262-PCT1 ST25.txt”, which is 29 Kbytes in size, and which was created on May 27, 2015 in the IBM-PC machine format, having an operating system compatibility with MS-Windows, and is submitted herewith.FIELD OF THE INVENTION[0002]The invention, in some embodiments, relates to methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/113A61K9/00A61K31/713A61K45/06
CPCC12N15/1135A61K45/06A61K9/0019A61K31/713C12N2310/317C12N2320/30C12N2310/321C12N2310/319C12N2310/14A61K45/00C12N2310/3521C12N2310/3515A61P13/12A61P43/00A61P7/02A61P9/10A61K48/00A61K31/712A61K39/395A61K31/436
Inventor SQUIERS, ELIZABETH C.ERLICH, SHAIROTHENSTEIN, DANIELSHARON, NIRODENHEIMER, DANIEL J.FEINSTEIN, ELENA
Owner QUARK FARMACUITIKALS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com